Introduction {#s0005}
============

Surgical resection, radiotherapy and adjuvant chemotherapy are the main treatments for colorectal cancer [@bb0005]. Currently, oxaliplatin (OXA) in combination with 5-fluorouracil (5-FU) and leucovorin (LV), termed FOLFOX, showed response rates of more than 50% and increased the survival rate of colorectal cancer [@bb0010], [@bb0015]. The FOLFOX chemotherapy regimen has become first-line protocol for adjuvant treatment of colorectal cancer [@bb0020]. However, colon-cancer patients develop tumor recurrence [@bb0025], [@bb0030], [@bb0035]. Therefore, more effective therapy strategies are needed for advanced colorectal cancer.

To accomplish this goal, we have developed the patient-derived orthotopic xenograft (PDOX) nude mouse model for all cancer types [@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080], [@bb0085]. To improve efficacy of chemotherapy on colorectal cancer patient, the colorectal cancer PDOX and cell- line orthotopic nude-mouse models were developed [@bb0085], [@bb0090], [@bb0095], [@bb0100], [@bb0105], [@bb0110], [@bb0115], [@bb0120].

Pazopanib (PAZ) is an orally-available, multi-targeted targeted tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFRs), including VEGFR-1, VEGFR-2 and VEGFR-3, to which it has high affinity [@bb0125]. PAZ can inhibit the receptors of platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) receptor and c-kit [@bb0130], [@bb0135], [@bb0140]. Bennouna et al. [@bb0145] reported that PAZ could be safely given in combination with irinotecan to patients with advanced colorectal cancer. Fu et al. [@bb0150] also showed that PAZ could be safe for patients with metastasis colorectal cancer in a Phase I study [@bb0150]. Zhang et al. [@bb0155] reported that PAZ directly inhibited colon cancer cells in vitro.

Temozolomide (TEM) is an oral alkylating agent with a broad spectrum of antitumor activity [@bb0160]. TEM targets methylation and induces apoptosis [@bb0160]. TEM has been used in the treatment of patients with glioblastoma [@bb0165], [@bb0170], metastatis melanoma [@bb0175] and pancreatic neuroendocrine tumors [@bb0180]. However, the use of TEM is controversial in colorectal cancer [@bb0185], [@bb0190].

In the present study, we identified a therapeutics strategy with the combination of TEM + PAZ + FOLFOX in a colorectal cancer PDOX nude-mouse model.

Materials and Methods {#s0010}
=====================

Mice {#s0015}
----

In this study, transgenic green fluorescence protein (GFP)-expressing and non-transgenic athymic nu/nu mice, 4 to 6 weeks old, were used. All mice were obtained from AntiCancer Inc. (San Diego, CA, USA). Mouse housing, feeding, and surgical procedures were performed as previously described [@bb0080], [@bb0195], [@bb0200]. The mice were observed on a daily basis and humanely sacrificed as previously described [@bb0200]. All animal experiments were carried out in accordance with AntiCancer Inc. Institutional Animal Care and Use Committee (IACUC)-protocol specifically approved for this study, and in accordance with the principles and procedures outlined in the National Institutes of Health Guidelines for care and Use of Animals under Assurance Number A3873--1 [@bb0075] as previously described [@bb0200].

Patient-Derived Tumor {#s0020}
---------------------

The primary colorectal cancer tumor samples were previously obtained in the Division of Surgical Oncology, University of California, San Diego (UCSD) from a patient who did not receive any chemotherapy or radiotherapy before surgery [@bb0110], [@bb0120]. Informed patient consent and Institutional Review Board (IRB) approval was obtained before surgery. Using the surgical orthotopic implantation (SOI) technique a colorectal cancer PDOX mouse model was established, as previously reported [@bb0205].

Establishment of an Imageable Colorectal Cancer PDOX Nude Mouse Model {#s0025}
---------------------------------------------------------------------

Colorectal cancer tissues were cut into 5 mm^3^ fragments and seeded subcutaneously in nude mice. The colorectal cancer tumors grown in nude mice were then harvested, cut into 5 mm^3^ fragments, and implanted subcutaneously nude mice expressing green fluorescence protein [@bb0210], [@bb0215]. After two passages in GFP-expressing nude mice, colorectal cancer tumors containing GFP-expressing stromal cells, were harvested and cut into 5 mm^3^ fragments [@bb0220]. After that non-GFP-expressing nude mice were anesthetized with ketamine-mixed drug (20 mg/kg ketamine, 15.2 mg/kg xylazine, and 0.48 mg/kg acepromazine maleate), and an approximately 1 cm skin incision was made at the middle of the abdomen. A 5 mm^3^ tumor fragment was sutured on the cecum. The incision was closed using 6--0 nylon sutures as previously described [@bb0205]. The schematic diagram to establish a colorectal cancer PDOX model is shown in [Figure 1](#f0005){ref-type="fig"}*A*.Figure 1Establishment of an imageable patient-derived orthotopic xenograft (PDOX) model of colon cancer and the drug treatment schema. (A) Schematic illustration of subcutaneous and surgical orthotopic implantation (SOI) to establish an imageable PDOX (iPDOX) model of human colorectal cancer. (B) Treatment regimen and quantitative drug efficacy. Treatment protocol. G1: untreated control; G2: treated with TEM + PAZ (TEM 25 mg/kg, oral.; PAZ 50 mg/kg, oral, daily for 3 weeks); G3: treated with FOLFOX (OXA 6 mg/kg, ip., LV 90 mg/kg, ip.; 5-FU 50 mg/kg, ip.; weekly for 2 weeks); G4: treated with TEM + PAZ + FOLFOX(TEM 25 mg/kg, oral.; PAZ 50 mg/kg, oral, daily for 3 weeks; OXA 6 mg/kg, ip., LV 90 mg/kg, ip.; 5-FU 50 mg/kg, ip.; weekly for 2 weeks). All treated mice were sacrificed on the endpoint day, and tumors were resected for further histological accession.Figure 1

Treatment Study Design in the Colorectal Cancer PDOX Nude Mouse Model {#s0030}
---------------------------------------------------------------------

Six weeks after orthotopic implantation of colorectal cancer-GFP tumors, the abdomen of the PDOX mice was opened to measure tumor growth. The PDOX mice were randomized into 4 groups (5 mice/per treatment group) by measuring tumor size: Group 1 (G1), control group (no treatment); Group 2 (G2), TEM + PAZ (TEM 25 mg/kg, oral; PAZ 50 mg/kg, oral, daily for 3 weeks); Group 3 (G3), FOLFOX (OXA 6 mg/kg, ip., LV 90 mg/kg, ip.; 5-FU 50 mg/kg, ip.; weekly for 2 weeks); Group 4 (G4), TEM + PAZ + FOLFOX (TEM 25 mg/kg, oral.; PAZ 50 mg/kg, oral, daily for 3 weeks; OXA 6 mg/kg, ip., LV 90 mg/kg, ip.; 5-FU 50 mg/kg, ip.; weekly for 2 weeks) ([Figure 1](#f0005){ref-type="fig"}*B*). Tumor length, width and mouse body weight was measured once per week. Tumor volume was calculated with the following formula: Tumor volume (mm^3^) = length (mm) × width (mm) × width (mm)/2. Data are presented as mean ± standard deviation (SD). Mice were imaged with the FluorVivo imaging system (INDEC Bio Systems, Santa Cruz, CA, USA.) [@bb0225].

Hematoxylin and Eosin (H&E) Staining {#s0035}
------------------------------------

Before sectioning and staining, fresh tumor samples were fixed in 10% formalin and embedded in paraffin. Tumor tissue sections (4 μm) slices were deparaffinized in xylene and rehydrated in an ethanol series. Hematoxylin and eosin (H&E) staining was performed according to a standard protocol. Histological observation and imaging was carried out with a BHS microscope system (Olympus Corporation, Tokyo, Japan) and images were analyzed with INFINITY ANALYZE software (Lumenera Corporation, Ottawa, Canada) [@bb0230].

Immunohistochemistry (IHC) and Evaluation {#s0040}
-----------------------------------------

4-μm-thick serial sections were deparaffinized in xylene and rehydrated in ethanol series. Antigen retrieval was performed by heating in sodium citrate (pH 6.0) and then blocked by non-specific antigen. Thereafter, primary rabbit polyclonal anti-mouse LYVE-1antibody (1:400, Abcam, Cambridge, MA, USA) was incubated with slices overnight in a humidified box at 4 °C, followed by incubation with biotinylated goat anti-polyvalent. Sections were incubated with streptavidin peroxidase for 10 min in DAB for 1--8 min, and in hematoxylin for 2 min. All steps were performed in accordance with the protocol of a rabbit specific HRP/DAB (ABC) detection IHC kit (Abcam, Cambridge, MA, USA) at room temperature. Lymphatic vessels counting was carried out as previously descried [@bb0235]. Specimens were imaged with a BHS system microscope Images were analyzed with INFINITY ANALYZE software (Lumenera Corporation, Ottawa, Canada).

Statistical Analysis {#s0045}
--------------------

All statistical analyses were performed using GraphPad Prism 5 software (GraphPad Software, Inc. La Jolla, CA, USA). The one-way analysis of variance (ANOVA) with Tukey\'s post hoc test was used when more than two groups were compared. The paired t-test was used for the parametric test to compare the means between two related groups. The data are expressed as the mean ± SD. A *p*-value of less than 0.05 or less is considered statistically significant.

Results {#s0050}
=======

Drug Efficacy on the Colorectal Cancer PDOX {#s0055}
-------------------------------------------

At the endpoint of treatment, the tumor volumes were: G1, untreated control, 540 ± 110.5 mm^3^; G2, TEM + PAZ, 293.8 ± 17.8 mm^3^; G3, FOLFOX, 268.6 ± 46.2 mm^3^; G4, TEM + PAZ + FOLFOX, 102.8 ± 11.1 mm^3^. The untreated control group (G1) tumors grew approximately 5 times larger compared to initiation of treatment. In the TEM + PAZ (G2) and FOLFOX groups, at the end point, there was a significant inhibition in tumor growth compared to the control group (*P* \< 0.001). The TEM + PAZ + FOLFOX combination group (G4) significantly regressed tumor growth compared to the control group *P* \< 0.001) ([Figure 2](#f0010){ref-type="fig"}). The TEM + PAZ + FOLFOX group (G4) had a greater inhibition of tumor growth than the TEM + PAZ group (G2) or FOLFOX group (G3) (*P \<*0.01) ([Figure 2](#f0010){ref-type="fig"}).Figure 2Imaging PDOX tumors treated with each drug, and quantitative efficacy of chemotherapy on the colorectal cancer PDOX model. Images of representative PDOX mouse models from each group at the endpoint. Arrows indicate GFP-expressing tumor stromal cells. (A) G1: untreated control; G2: treated with TEM + PAZ; G3: treated with FOLFOX; G4: treated with TEM + PAZ + FOLFOX. The FluorVivo imaging System was used. (B) Line graphs indicate relative tumor volume (ratio tumor volume at each time point to volume at initiation of treatment) for each drug and control group. n = 5 mice/group. \*\**P* \< 0.01; \*\*\**P* \< 0.001.Figure 2

Effect of Treatment on Body Weight {#s0060}
----------------------------------

To determine whether the drug treatments had an effect on body weight, we measured the mouse body weight pre-treatment and post-treatment. Final body weight of mice in the untreated control group increased compared to the initial body weight (*P* \< 0.05) ([Figure 3](#f0015){ref-type="fig"}). Mice treated with TEM + PAZ + FOLFOX also decreased their body weight compared to the initial body weight (*P* \< 0.05) ([Figure 3](#f0015){ref-type="fig"}). There was no significant difference in body weight among the TEM + PAZ and FOLFOX groups ([Figure 3](#f0015){ref-type="fig"}). There were no animal deaths in any group.Figure 3Effect of drugs on mouse body weight. Bar graph shows body weight in each group at pre-treatment and post-treatment. n = 5 mice/group. \**P* \< .05.Figure 3

Tumor Histology Analysis Colorectal Cancer PDOX {#s0065}
-----------------------------------------------

Histologically, the control group tumor mainly comprised viable cancer cells ([Figure 4](#f0020){ref-type="fig"}*A*). In the tumors treated with FOLFOX, the cancer-cell density was lower than the TEM + PAZ group ([Figure 4](#f0020){ref-type="fig"}, *B* and *C*). In all treated groups (G2, G3 and G4), cancer-cell density was lower than the control ([Figure 4](#f0020){ref-type="fig"}, *B*--*D*). The strongest reduction in cancer cell density was observed when colorectal cancer PDOX tumors were treated with the combination of TEM + PAZ + FOLFOX ([Figure 4](#f0020){ref-type="fig"}*D*).Figure 4Histology of colorectal cancer PDOX mouse model in treated and untreated tumors. Hematoxylin and eosin (H&E)-stained sections of the (A) Untreated control group. (B) TEM + PAZ-treated group. (C) FOLFOX-treated group, and (D) TEM + PAZ + FOLFOX-treated group. Microscope magnification 200×.Figure 4

PAZ Inhibited the Lymphatic Vessel Density (LVD) and Lymphangiogenesis in the Colorectal Cancer PDOX Mouse Model {#s0070}
----------------------------------------------------------------------------------------------------------------

The lymphatic vessel density (LVD) and lymphangiogenesis of colorectal cancer PDOX tumors were marked by LYVE-1 antibodies using immunohistochemical staining. Tumors treated with PAZ in G2 and G4 groups had a significantly lower lymphatic vessel density (LVD) compared to groups G1 and G3 (*P* \<0.01) ([Figure 5](#f0025){ref-type="fig"}). These results suggest that PAZ could inhibit lymphangiogenesis of colorectal cancer in a PODX mouse model.Figure 5PAZ inhibits lymphangiogenesis of a colorectal cancer PDOX mouse model. (A) Representative lymphatic vessel stained with endothelial hyaluronic acid receptor 1 (LYVE-1) in the control group. (B) Lymphatic vessels stained in TEM + PAZ group. (C) Lymphatic vessels stained in FOLFOX group. (D) Lymphatic vessels stained in TEM + PAZ + FOLFOX group. (E) Bars with LYVE-1 lymphatic vessel staining density. Arrows indicate lymphatic vessels. Magnification 200×. *\*\*P* \<0.01.Figure 5

Discussion {#s0075}
==========

Although FOLFOX is first-line treatment for colorectal cancer, there is still recurrence and metastasis of tumors due to resistance to OXA or 5-FU \[[@bb0240]\] . Several studies showed that TEM [@bb0245], [@bb0250] and PAZ [@bb0150], [@bb0155] could effectively inhibit the progression of colorectal cancer. In the present study, we found that TEM and PAZ combined with FOLFOX can regress a colorectal cancer in a PDOX mouse model. This is the first study which shows that the TEM + PAZ + FOLFOX combination is effective in colorectal cancer using a colorectal cancer PDOX mouse model.

TEM is easily absorbed in the digestive tract after oral administration with bioavailability almost 100%. TEM has been approved for glioblastoma [@bb0255], [@bb0260], sarcoma [@bb0265], [@bb0270] as well as melanoma \[[@bb0175]\]. We previously reported that TEM was effective in PDOX mouse models of sarcoma and melanoma \[[@bb0200], [@bb0275], [@bb0280], [@bb0285], [@bb0290], [@bb0295], [@bb0300], [@bb0305], [@bb0310], [@bb0315], [@bb0320], [@bb0330]\].

We previously also reported that PAZ was effective in PDOX model of sarcomas \[[@bb0230], [@bb0305], [@bb0310], [@bb0315]\]. PAZ has a high affinity with VEGFR-1/2/3, which can inhibit the signaling pathway induced by VEGFRs and regulate corresponding physiological functions [@bb0125]. We found that the LYVE-1 staining was reduced in the G2 and G4 groups compared to the G1 and G3 groups, suggesting that PAZ could inhibit the lymphangiogenesis.

Our results suggest that the TEM + PAZ + FOLFOX combination has clinical potential for patient with colorectal cancer and also show the importance of PDOX models for individualized therapy. The detection of the PDOX model was increased by initial growth of the tumor in transgenic nude mice expression a fluorescent protein [@bb0210], [@bb0215], [@bb0220].

The reduction in lymphangiogenesis and no death in the treated groups suggest that the combination of TEM + PAZ + FOLFOX is superior. However, we have not tested the survival within the treated groups. However, based on the final tumor volume, high efficacy is very clear in that combination of TEM + PAZ + FOLFOX regressed the tumor. Survival studies will be done in future experiments.

Conclusions {#s0080}
===========

Our results together suggest that TEM + PAZ + FOLFOX combination is a novel effective treatment for colorectal cancer in a PDOX mouse model. We also found that therapy regimen including PAZ could inhibit lymphangiogenesis in the colorectal cancer PDOX mouse model.
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